Necitumumab

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).^[3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).^[4][5][2] It was counterproductive in non-squamous non-small-cell lung carcinoma.^[2][6]

Necitumumab

Necitumumab Fab (blue) bound to EGFR (green). PDB: 6B3S​
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	EGFR
Clinical data
Trade names	Portrazza
AHFS/Drugs.com	Multum Consumer Information
License data	US DailyMed: Necitumumab
Routes of administration	Intravenous infusion
ATC code	L01FE03 (WHO)
Legal status
Legal status	CA: ℞-only[1] US: ℞-only[2]
Pharmacokinetic data
Elimination half-life	~14 days
Identifiers
CAS Number	906805-06-9 N
DrugBank	DB09559 Y
ChemSpider	none
UNII	2BT4C47RUI
KEGG	D10018 N
Chemical and physical data
Formula	C6436H9958N1702O2020S42
Molar mass	144844.87 g·mol−1
NY (what is this?)  (verify)